# US 10,369,212 B2 · H3 influenza A virus > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,369,212 B2 - Document ID: US10369212B2 - Status: Granted - Kind: B2 - Application number: 16/015,504 - Filed: 2018-06-22 - Published: 2018-10-18 - Granted: 2019-08-06 - Earliest claimed: 2005-01-11 - Assignees: Wisconsin Alumni Research Foundation (WARF) - Applicants: Wisconsin Alumni Research Foundation (WARF) - Inventors: Christopher W. Olsen; Gabriele A. Landolt; Alexander I. Karasin - Web page: https://patentgrep.com/patent/US10369212B2 ## CPC - A61K 39/145: Orthomyxoviridae, e.g. influenza virus - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 9/0043: {Nose} - A61K 39/12: Viral antigens - C07K 14/005: from viruses - C12N 1/00: Microorganisms; Compositions thereof (medicinal preparations containing material from protozoa, bacteria or viruses A61K35/66, from algae A61K36/02, from fungi A61K36/06; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines, A61K39/00); Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - G01N 33/56983: {Viruses} - A61K 2039/525: {Virus} - A61K 2039/5252: {inactivated (killed)} - A61K 2039/5254: {avirulent or attenuated} - A61K 2039/54: {characterised by the route of administration} - A61K 2039/543: {intranasal} - A61K 2039/552: {Veterinary vaccine} - A61K 2039/70: {Multivalent vaccine} - C12N 2760/16121: Viruses as such, e.g. new isolates, mutants or their genomic sequences - C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C12R 2001/91: Cell lines {; Processes using cell lines} - G01N 2333/11: Orthomyxoviridae, e.g. influenza virus - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS ## Abstract The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof. ## Claims ### Claim 1 A vaccine comprising an isolated H3 influenza virus comprising HA-1 having a sequence having at least 96% amino acid sequence identity to the HA-1 portion of SEQ ID NO: 1 and having an alanine at position 78 and a serine at position 159, in an amount effective to induce a prophylactic or therapeutic response against influenza infection, wherein the virus is inactivated, the vaccine is in freeze-dried form or the vaccine further comprises an adjuvant. ### Claim 2 (depends on 1) The vaccine of claim 1 wherein the HA-1 sequence further comprises a residue other than methionine at position 29, a residue other than lysine at position 54, a residue other than serine at position 83, a residue other than asparagine at position 92, a residue other than leucine at position 222, a residue other than alanine at position 272, or a residue other than threonine at position 328. ### Claim 3 (depends on 1) The vaccine of claim 1 wherein the HA-1 sequence has at least 97% amino acid sequence identity to the HA-1 portion of SEQ ID NO: 1. ### Claim 4 (depends on 1) The vaccine of claim 1 further comprising a different isolated influenza virus. ### Claim 5 (depends on 1) The vaccine of claim 1 wherein the virus is inactivated. ### Claim 6 (depends on 1) The vaccine of claim 1 which comprises the adjuvant. ### Claim 7 (depends on 1) The vaccine of claim 1 further comprising a pharmaceutically acceptable carrier. ### Claim 8 (depends on 7) The vaccine of claim 7 wherein the carrier is suitable for intranasal or intramuscular administration. ### Claim 9 (depends on 1) The vaccine of claim 1 which is in freeze-dried form. ### Claim 10 (depends on 1) The vaccine of claim 1 wherein the virus comprises at least one of the following viral segments: a viral segment with sequences for a NA having SEQ ID NO:2 or having at least 95% amino acid sequence identity to SEQ ID NO:2, a viral segment with sequences for a PB1 having SEQ ID NO:3 or having at least 95% amino acid sequence identity to SEQ ID NO:3, a viral segment with sequences for a PB2 having SEQ ID NO:4 or having at least 95% amino acid sequence identity to SEQ ID NO:4, a viral segment with sequences for a PA having SEQ ID NO:5 or having at least 95% amino acid sequence identity to SEQ ID NO:5, a viral segment with sequences for a NP having SEQ ID NO:6 or having at least 95% amino acid sequence identity to SEQ ID NO:6, a viral segment with sequences for a M1 having SEQ ID NO:7 or having at least 95% amino acid sequence identity to SEQ ID NO:7, a viral segment with sequences for a M2 having SEQ ID NO: 17 or having at least 95% amino acid sequence identity to SEQ ID NO: 17, a viral segment with sequences for a NS1 having SEQ ID NO:8 or having at least 95% amino acid sequence identity to SEQ ID NO:8, or a viral segment with sequences for a NS2 having SEQ ID NO: 18 or having at least 95% amino acid sequence identity to SEQ ID NO:18. ### Claim 11 A method to immunize a mammal against influenza, comprising administering to the mammal an effective amount of a composition comprising an isolated H3 influenza virus comprising HA-1 having a sequence having at least 96% amino acid sequence identity to the HA-1 portion of SEQ ID NO:1 and having an alanine at position 78 and a serine at position 159. ### Claim 12 (depends on 11) The method of claim 11 wherein the HA-1 sequence has a residue other than methionine at position 29, a residue other than lysine at position 54, a residue other than serine at position 83, a residue other than asparagine at position 92, a residue other than leucine at position 222, a residue other than alanine at position 272, or a residue other than threonine at position 328. ### Claim 13 (depends on 11) The method of claim 11 wherein the mammal is a dog. ### Claim 14 (depends on 11) The method of claim 11 wherein the mammal is a horse. ### Claim 15 (depends on 11) The method of claim 11 wherein the composition further comprises a different influenza virus. ### Claim 16 (depends on 11) The method of claim 11 wherein the H3 influenza virus is an attenuated virus or is a reassortant virus. ### Claim 17 (depends on 11) The method of claim 11 wherein the composition further comprises an adjuvant or a pharmaceutically acceptable carrier. ### Claim 18 (depends on 11) The method of claim 11 wherein the carrier is suitable for intranasal or intramuscular administration. ### Claim 19 (depends on 11) The method of claim 11 wherein the composition further comprises a pathogen other than the H3 influenza virus. ### Claim 20 A method of preparing a vaccine, comprising combining an isolated H3 influenza virus comprising HA-1 having a sequence having at least 96% amino acid sequence identity to the HA-1 portion of SEQ ID NO: 1 and having an alanine at position 78 and a serine at position 159, with an adjuvant or a pharmaceutically acceptable carrier, or treating the isolated H3 influenza virus with an agent that inactivates the isolated H3 virus or under conditions that freeze-dry the isolated H3 virus, thereby providing a composition; and providing an individual dose of the composition comprising an amount of the H3 influenza virus effective to immunize a canine or a horse.